Clinical Trial Update: An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders [Phase 2]

View source ↗

Summary

Status update: an open-label extension study of STX209 (arbaclofen placarbil) in autism spectrum disorders has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autism Spectrum Disorder

Drugs mentioned

• STX209 (arbaclofen)

Snippet

Sponsor: Seaside Therapeutics, Inc. | Conditions: Autism Spectrum Disorders | Phase 2 | Status: TERMINATED